Xcout Intel
Glycomine, Inc.
Glycomine, Inc. is a biotherapeutics company focused on developing replacement therapies and treatments for serious rare genetic diseases, operating out of major life science hubs in San Francisco and Boston.
Subscribe to see Glycomine, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Glycomine, Inc. at a glance
Glycomine, Inc. is a biopharma company headquartered in United States. Its most recent funding round, Series C, raised $115M in April 2025. Xcout tracks 16 named people at Glycomine, Inc., including Steve Axon (CEO).
Glycomine, Inc. leadership
- Steve AxonCEO
- Steven AxonChief Executive Officer
- Geoffrey HirdChief Technology Officer
- Hicham AlaouiChief Scientific Officer
- Peter McWilliamsChief Business Officer
- Rose MarinoChief Medical Officer
10 more named people on record for Glycomine, Inc., with roles, board committees and tenure — see the full roster →
Glycomine, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $115M | 11 named | |
| — | $68M | 11 named | |
| SEC Form D filing | $4.9M | — | |
| Series A | $12M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Glycomine, Inc. competitors
A few of Glycomine, Inc.'s closest competitors — see the full list of competitors and alternatives →
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Scout Bio, Inc. is a veterinary biotechnology company specializing in animal health and advanced gene therapy treatments currently being evaluated in clinical trials.
Orbital Therapeutics is a biotechnology company developing RNA medicines, with a focus on engineered circular RNA and delivery technologies. Its programs are intended to address diseases that may benefit from durable, programmable protein expression, serving patients and healthcare providers through potential therapeutic products.
Astria Therapeutics, Inc. is a public biopharmaceutical company headquartered in Boston, Massachusetts, dedicated to developing life-changing therapies for patients.
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered in Boston, Massachusetts. The company discovers and develops Anticalin-based drugs designed to address significant medical needs.
Get Glycomine, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Glycomine, Inc. in Xcout Intel
- 16 named people with titles, LinkedIn and board committees
- 4 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access